Skip to main content
Journal cover image

Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction.

Publication ,  Journal Article
Belkin, RN; Mark, DB; Aronson, L; Szwed, H; Califf, RM; Kisslo, J
Published in: Am J Cardiol
March 1, 1991

The effect of thrombolytic therapy on the frequency, time course and sequelae of pericardial effusion after myocardial infarction are unknown. A prospective, serial, 2-dimensional echocardiographic study of patients with myocardial infarction who received recombinant tissue-type plasminogen activator (rt-PA) was undertaken to address this issue. The study population comprised 52 of the 112 patients enrolled in the first Thrombolysis and Angioplasty in Myocardial Infarction trial at Duke University Medical Center. Enrollment in the serial echocardiography protocol was determined by equipment and support staff availability. Complete echocardiographic studies were performed within 90 minutes after initiation of thrombolytic therapy (day 0), and on days 1, 3 and 6. Patients undergoing serial echocardiography did not differ in demographic or clinical characteristics from those who did not. Pericardial effusion was present in 3 of 38 patients (8%) at day 0, in 2 of 44 (5%) at day 1, in 8 of 43 (19%) at day 3, and in 10 of 42 (24%) at day 6. By day 6, 3 of 10 pericardial effusions were moderate in size, 1 of 10 was large and the remainder were small. No patients developed echocardiographic or hemodynamic signs of cardiac tamponade. The prevalence and time course of pericardial effusion among patients with acute myocardial infarction who received rt-PA in this study are similar to observations reported in earlier studies in which patients did not receive thrombolytic therapy. Adverse sequelae of pericardial effusion after thrombolytic therapy are rare.

Duke Scholars

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

March 1, 1991

Volume

67

Issue

6

Start / End Page

496 / 500

Location

United States

Related Subject Headings

  • Tissue Plasminogen Activator
  • Thrombolytic Therapy
  • Prospective Studies
  • Pericardial Effusion
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Belkin, R. N., Mark, D. B., Aronson, L., Szwed, H., Califf, R. M., & Kisslo, J. (1991). Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction. Am J Cardiol, 67(6), 496–500. https://doi.org/10.1016/0002-9149(91)90010-i
Belkin, R. N., D. B. Mark, L. Aronson, H. Szwed, R. M. Califf, and J. Kisslo. “Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction.Am J Cardiol 67, no. 6 (March 1, 1991): 496–500. https://doi.org/10.1016/0002-9149(91)90010-i.
Belkin RN, Mark DB, Aronson L, Szwed H, Califf RM, Kisslo J. Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction. Am J Cardiol. 1991 Mar 1;67(6):496–500.
Belkin, R. N., et al. “Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction.Am J Cardiol, vol. 67, no. 6, Mar. 1991, pp. 496–500. Pubmed, doi:10.1016/0002-9149(91)90010-i.
Belkin RN, Mark DB, Aronson L, Szwed H, Califf RM, Kisslo J. Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction. Am J Cardiol. 1991 Mar 1;67(6):496–500.
Journal cover image

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

March 1, 1991

Volume

67

Issue

6

Start / End Page

496 / 500

Location

United States

Related Subject Headings

  • Tissue Plasminogen Activator
  • Thrombolytic Therapy
  • Prospective Studies
  • Pericardial Effusion
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans
  • Female